Incyte (WBO:INCY) Accumulated other comprehensive income (loss) : €-6 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Incyte Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Incyte's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was €-6 Mil.

Incyte's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2023 (€21 Mil) to Dec. 2023 (€12 Mil) and declined from Dec. 2023 (€12 Mil) to Mar. 2024 (€-6 Mil).

Incyte's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 (€-17 Mil) to Dec. 2022 (€14 Mil) but then declined from Dec. 2022 (€14 Mil) to Dec. 2023 (€12 Mil).

Incyte Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Incyte's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Accumulated other comprehensive income (loss) Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-13.99

-12.63

-17.22

14.23

12.02

Incyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															19.56	24.74	21.45	12.02	-5.68

Incyte Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Incyte Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Incyte's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (WBO:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.